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Aims: Sphingolipid and oxidant signaling affect glucose uptake, atrophy, and force production of skeletal
muscle similarly and both are stimulated by tumor necrosis factor (TNF), suggesting a connection
between systems. Sphingolipid signaling is initiated by neutral sphingomyelinase (nSMase), a family of
agonist-activated effector enzymes. Northern blot analyses suggest that nSMase3 may be a striated
muscle-speciﬁc nSMase. The present study tested the hypothesis that nSMase3 protein is expressed in
skeletal muscle and functions to regulate TNF-stimulated oxidant production.
Results: We demonstrate constitutive nSMase activity in skeletal muscles of healthy mice and humans
and in differentiated C2C12 myotubes. nSMase3 (Smpd4 gene) mRNA is highly expressed in muscle. An
nSMase3 protein doublet (88 and 85 kD) is derived from alternative mRNA splicing of exon 11. The
proteins partition differently. The full-length 88 kD isoform (nSMase3a) fractionates with membrane
proteins that are resistant to detergent extraction; the 85 kD isoform lacking exon 11 (nSMase3b) is more
readily extracted and fractionates with detergent soluble membrane proteins; neither variant is detected
in the cytosol. By immunoﬂuorescence microscopy, nSMase3 resides in both internal and sarcolemmal
membranes. Finally, myotube nSMase activity and cytosolic oxidant activity are stimulated by TNF. Both if
these responses are inhibited by nSMase3 knockdown.
Innovation: These ﬁndings identify nSMase3 as an intermediate that links TNF receptor activation,
sphingolipid signaling, and skeletal muscle oxidant production.
Conclusion: Our data show that nSMase3 acts as a signaling nSMase in skeletal muscle that is essential
for TNF-stimulated oxidant activity.
Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Membrane sphingolipids such as sphingomyelin play an im-
portant role in cell signaling. Hydrolysis of sphingomyelin leads to
generation of sphingolipid signaling molecules, e.g. ceramide,access article under the CC BY lice
resis; VDAC, voltage depen-
equence.
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Performance, University ofsphingosine, sphingosine-1-phosphate. These effectors participate
in pathways that regulate proliferation [46], apoptosis [26], cell
cycle arrest [27], regeneration [2], glucose uptake [58], insulin
resistance [48], viral uptake [3], immune response [4], vascular
tone [60], mechanotransduction [12], aging [42], and memory [57].
Studies have shown that neutral sphingomyelinase 2 (nSMase2) is
a predominant enzyme involved in these regulatory processes.
nSMase2 hydrolyzes sphingomyelin in response to biological
stimuli in liver, brain, immune cells, and other non-muscle cell
types [9,14,29,30,44,45,55,59].
Recently, sphingolipid signaling has been implicated in skeletal
muscle functions like oxidant production [17], glucose uptake
[1,22], muscle cell adaptation [13,24,56], and force generation
[17]. Exogenous nSMase causes a depression in diaphragm speciﬁcnse (http://creativecommons.org/licenses/by/3.0/).
J.S. Moylan et al. / Redox Biology 2 (2014) 910–920 911force that is suppressed by antioxidants [17]. In addition, nSMase
activity may suppress myoblast differentiation [56] and stimulate
muscle atrophy [13]. Correspondingly, nSMase activity is reduced
after exercise [24].
Although it is clear that sphingolipid signaling plays a role in
muscle function, nSMase2 appears to be of limited abundance in
skeletal muscle [25]. Another nSMase, nSMase3, is reported to be
highly expressed in heart and skeletal muscle [31]. However, the
biochemistry of nSMase3 has not been widely studied. Over-
expressed nSMase3 localizes to the endoplasmic reticulum (ER)
and Golgi in breast (MCF-7) cancer cells [31]. Endogenous
nSMase3 is found in mitochondrial-associated ER membranes in
HeLa cells [8]. Overexpressed nSMase3 is activated by short
(within 2 min) [31] but not long-term (14 h) [9] exposure to TNF.
In addition, overexpression of nSMase3 enhances TNF- [8] and
Adriamycin-induced apoptosis [11].
Our current study aimed to determine if nSMase3 contributes
to redox signaling in skeletal muscle. Sphingolipid and oxidant
signaling are stimulated by pro-inﬂammatory cytokines and seem
to affect similar processes in skeletal muscle, e.g. glucose uptake
[1,7,22], force production [17,54], and fatigue [17,51]. We therefore
hypothesized that nSMase3 regulates TNF-stimulated oxidant
production in skeletal muscle. We tested this hypothesis by
addressing three questions: (1) Is nSMase3 expressed in skeletal
muscle? (2) Does endogenous nSMase3 protein exhibit nSMase
activity? (3) Is TNF-induced oxidant production mediated by
nSMase3?Materials and methods
Humans
Studies of human muscle were conducted at the University of
Kentucky after approval by the Institutional Review Board. Dia-
phragm tissue biopsies were obtained from heart transplant organ
donors after obtaining informed consent according to institutional
guidelines.Animals
Studies were conducted at the University of Kentucky after
approval by the Institutional Animal Care and Use Committee.
Adult male C57BL/6J mice (6–8 week old, Harlan, Indianapolis, IN)
were maintained by the Division of Laboratory Animal Resources
in a 12:12 h dark:light cycle and received water and food ad
libitum. Mice were deeply anesthetized by inhalation of isoﬂurane
(Aerrane, Baxter Healthcare) and killed by exsanguination follow-
ing cervical dislocation. Muscle tissues were harvested for enzyme
activity assays and analysis of mRNA and protein.Myotubes
Myoblasts from the murine skeletal muscle-derived C2C12 cell
line (American Type Culture Collection, Rockville, MD) were
cultured as in Smith et al. [53]. Cells were seeded at 10,000 cells/
cm2 in Dulbecco’s modiﬁed Eagle’s medium with 1.6 g/l sodium
bicarbonate, 10% fetal bovine serum, and 100 U/ml PenStrep
(Invitrogen, Carlsbad, CA) in 5% CO2 at 37 °C. After 2 days, myoblast
cultures were serum restricted in FBS-free medium containing 2%
horse serum. Mature myotubes were obtained 5 days after serum
restriction. Medium was replaced every 48 h.nSMase activity
Cells (probe sonication, 5 s) or tissues (tissue homogenizer)
were lysed in 25 mM Tris pH 7.2, 1 mM EDTA, phosphatase and
protease inhibitor cocktails (Phosphatase Inhibitor Cocktails 2 and
3, Sigma-Aldrich, St. Louis, MO; Complete tablet, Roche Applied
Science, Indianapolis, IN). Protein concentration was assessed
using Coomassie Plus (Pierce-Thermo Scientiﬁc, Rockford, IL). We
ﬁnd that Triton X-100 obscures muscle nSMase activity. Accord-
ingly, detergent was omitted from all isolation and assay buffers.
nSMase activity was assessed using two methods. The NBD-
sphingomyelin method was used as described by Nikolova-Kar-
akashian et al. [43] and Merrill et al. [37]. Sample (20 mg protein)
was diluted into 30 ml assay buffer [25 mM Tris pH 7.5, 12 mM
MgCl2, 15 mM ﬂuorescent C6-NBD-sphingomyelin (6-((N-(7-nitro-
benz-2-oxa-1,3-diazol-4-yl) amino) hexanoyl) sphingosyl phos-
phocholine); Invitrogen] and incubated at 37 °C for 3 h. All reac-
tion buffers were supplemented with phosphatase, and protease
inhibitor cocktails. Reactions were stopped by the addition of
500 ml methanol (HPLC grade, Mallinckrodt, St. Louis, MO). After
further incubation at 37 °C for 30 min, the samples were centri-
fuged at 15,000g for 5 min and the generation of the ﬂuorescent
product, NBD-ceramide, was monitored by reverse phase HPLC
using methanol:water:phosphoric acid (850:150:0.15, by volume)
as a mobile phase [43].
The Amplex Red Sphingomyelinase Assay (Invitrogen, Carlsbad,
CA) measures activity by converting nSMase-generated phospho-
choline to choline with alkaline phosphatase, and choline to
betaine and H2O2 with choline oxidase. H2O2 plus horseradish
peroxidase act to oxidize non-ﬂuorescent Amplex Red to ﬂuores-
cent resoruﬁn. The assay was performed according to the manu-
facturer’s speciﬁcations with minor modiﬁcations. Sample (20 mg
protein) was diluted to 200 ml with assay mixture except that
Triton was omitted. The mixture, 7sphingomyelin substrate, was
incubated at 37 °C for 15–180 min and ﬂuorescence emissions at
600 nm (530 nm excitation) were measured every 15–30 min by
spectroﬂuorimeter (Synergy H1, Biotek, Winooski, VT). The ﬁrst
read was subtracted as baseline from subsequent reads. The
increase in ﬂuorescence caused by sphingomyelin supplementa-
tion reﬂected substrate-dependent phosphocholine release.
PCR
PCR analyses were performed as described [19,33]. RNA from
myotubes or muscle tissue was isolated with TRIzol (Invitrogen).
cDNA was synthesized using random hexamers or oligo dT and
M-MLV reverse transcriptase (Promega, Madison, WI). Target
mRNA was ampliﬁed using an Eppendorf Mastercycler (Haup-
pauge, NY) or quantiﬁed using the ABI 7500 Real, Time PCR System
(Applied Biosystems-Invitrogen). Isoform speciﬁc primers are
listed in Table 1. Primer efﬁciency was assessed by amplifying a
10-fold dilution series of target cDNA and plotting Ct values verses
log sample concentration. The slope of the standard curve was
used to calculate efﬁciency [efﬁciency¼(10(1/slope)1)100].
The abundance of target mRNA relative to rpl13A mRNA was
determined using the comparative cycle threshold method [20,36].
Western blots
As described [53], myotubes or muscle tissues were homo-
genized in 2 protein loading buffer (120 mM Tris pH 7.5,
200 mM DTT, 20% glycerol, 4% SDS, 0.002% bromphenol blue).
Equal amounts of protein were separated on 4–15% SDS-PAGE
(Criterion, BioRad). Proteins were either stained using Simply Blue
(Invitrogen) and scanned for total protein or transferred to PVDF
membranes for western blot using the Odyssey Infrared Imaging
Table 1
Oligonucleotide primers.
Real time PCR Forward (5′–3′) Reverse (5′–3′)
Mouse
nSMase1 CTCGCCGCCCTTGCT CAGCCGTAGAGAAAAGTTGAGCTT
nSmase2 CACCAACACCTCCATCAGTG GTCAGCCTGTTCTCCAGAGG
nSMase3 CCCTACGCACAGACCTTGTCA AAGACCTTAGCCACTCGGAAGA
nSMase3a ACCGACTCACTGTCTCCAGC GACTCTTGGTAGGCGTGGAG
nSMase3b CTCATGCCAAGGAGTCCTTC AAGGCATGCAGGTGCTTC
nSMase-MT TCATGGGAGTTACCCAGCTC CGACATTCATCCCCTTGTCT
rpl13A GCAAGTTCACAGAGGTCCTCAA GGCATGAGGCAAACAGTCTTTA
Human
nSMase1 TTTGGTGTCCGCATTGACTA TAGAGCTGGGGTTCTGCTGT
nSMase2 GGAAGGCCGAGGTGGAA CCCCCGAAGACACCATCA
nSMase3 CACCCAGGATGAGAATGGAAA GTCCGTCCTCACCCACGAT
nSMase-MT GAGCTAAGCCCTGGAGAGGT GACACTGAGACTCGGAGCTG
rpl13A TCCTGGTCTGAGCCCAATAAA CAGGGCAACAATGGAGGAA
Conventional PCR Forward (5′–3′) Reverse (5′–3′)
Human nSMase3
Exons 7–12 TCTTTGCCTTGAGCCTCATC ACCACCAACACATGCTCCTC
Exons 10–13 TGTTGAAATGTGGCTTCATCA GAGTTTCTGCTGGACGAACC
Mouse nSMase3
Exons 9–13 TTTGTGGAAATGTGGCTTCA CCTGTTTCTCAGGGGCATAC
Cloning primers Forward (5′–3′) Reverse (5′–3′)
ccgctcgagCTATGGCGTTCCCTCAC cgggatccTCAGAGCTGGTGCAGCTT
Morpholino oligos Antisense
nSMase2 ACAAAACCATTGCAGCTCATGGGC
nSMase3 TGAGGGAACGCCATAGCAGACTCCC
siRNA oligos Sense Antisense
nSmase3 exon 11 GAGGUUCUACACUACCGACtt GUCGGUAGUGUAGAACCUCca
nSmase3 exon 18 GAUCAUUAAUGGUCUGCGAtt UCGCAGACCAUUAAUGAUCtg
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normalized for total protein.
Cell fractionation
Myotube fractions were enriched for cytosolic proteins, deter-
gent-soluble proteins, and detergent-resistant proteins using the
FOCUS Global Fractionation kit according to the manufacturer’s
speciﬁcations with minor modiﬁcations (protocols A and C and
G-Biosciences, St. Louis, MO). Speciﬁcally, the detergent insoluble
pellet was resuspended in 2 protein loading buffer (see above).
Concentrated (6 ) protein loading buffer was added to the
cytosolic and soluble protein fractions. Biological structures in
the isolated fractions were assessed by western blot (Fig. 6) using
antibodies for proteins of the cytosol (p38 MAPK, p38 mitogen-
activated protein kinase), sarcolemma (TNFRI), endoplasmic reti-
culum (KDEL, ER targeting sequence), mitochondrial membrane
(VDAC, voltage dependent anion channel), Golgi (giantin), and
nucleus (lamin A/C).
Antibodies
Primary antibodies from commercial sources were mouse anti-
giantin, -VDAC (Abcam, Cambridge, MA), -ATP synthase α (Mitos-
ciences, Abcam) rabbit anti-lamin A/C, -p38 MAPK (Cell Signaling
Technologies, Danvers, MA); rabbit anti-nSMase3, -nSMase2,
mouse anti-annexin 2 (ECM Biosciences, Versailles, KY); and rabbit
anti-TNFR1 (Santa Cruz Biotechnology, Santa Cruz, CA). Secondary
antibodies were as follows: donkey anti-mouse Alexa 680 (Mole-
cular Probes-Invitrogen); goat anti-rabbit IRDye 800CW (LI-COR);donkey anti-rabbit DyLight 649; and donkey anti-mouse DyLight
549 (Jackson Immunoresearch, West Grove, PA).
nSMase3 silencing
nSMase3 expression was silenced as described [41,53] using
morpholino (Gene Tools, Philomath, OR) and siRNA (Silencer
Select, Ambion-Invitrogen) technologies. The morpholino spanned
the start codon. Independent siRNAs targeted nSMase3 exons 11
and 18 (Table 1 and Fig. 6). Cultured cells were transfected 3 days
after serum restriction using 10 mM morpholino plus Endo-Porter,
or 20 nM siRNA plus Oligofectamine (Invitrogen). Myotubes were
analyzed 48 h post-transfection.
Native gel electrophoresis
Myotubes were lysed as for nSMase assay (above). Samples
were diluted 1:1 with 2 native sample buffer (62.5 mM Tris,
pH 6.8; 25% glycerol; 0.01% Bromphenol Blue) and electrophoresed
through a 4–15% acrylamide gel (Criterion) using native running
buffer (25 mM Tris, 192 mM glycine). Separated proteins were
either transferred for western blotting (see above) or excised and
incubated directly in 200 ml Amplex Red nSMase assay buffer for
3 h (see above).
Immunoﬂuorescence microscopy
Muscle cross-sections (6 mm) were ﬁxed for 15 min at room
temperature in 4% paraformaldehyde, permeabilized using 1%
Triton X-100 for 15 min at 4 °C, and blocked for 2 h at room
temperature using 1% normal serum [19,40]. Prepared sections
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synthase-α (1:100), and annexin II (1:50). Secondary antibodies
were incubated for 45 min (donkey anti-rabbit DyLight 649;
donkey anti-mouse DyLight 594; 1:200). Sections were mounted
with ProLong Gold antifade reagent with HEK293 (Invitrogen) and
examined by ﬂuorescence microscopy (LSM 5 Live Microscope,
Zeiss, Thornwood, NY).
GFP-nSMase3 overexpression
Primers containing XhoI and BamHI restriction sites and span-
ning the start and stop codons (Table 1) were used to PCR-amplify
(Phusion High Fidelity Polymerase, New England Biolabs, Ipswich,
MA) oligo dT-primed cDNA from myotubes. The ampliﬁed frag-
ment was ligated into pAcGFP-C1 (Clontech, Mountain View, CA)
to generate an N-terminal GFP-nSMase3 fusion protein.
GFPnSMase3 plasmids were veriﬁed by DNA sequencing (Genewiz,
South Plainﬁeld, NJ). GFPnSMase3 or vector control was transi-
ently transfected into cells 3 days after serum restriction using
Lipofectamine LTX (Invitrogen). Myotubes were analyzed 72 h
post-transfection and the data were normalized for transfection
efﬁciency.
Cytosolic oxidant activity
Live-cell oxidant activity was measured as described [17,23].
The ﬂuorochrome probe 2′,7′-dichloroﬂuorescin diacetate (DCFH-
DA 10 mM, Molecular Probes-Invitrogen) was loaded into myotubes
15 min prior to treatment with TNF (6 ng/ml, 20 min) or vehicle.
Accumulation of the oxidized derivative DCF (excitation 480 nm,
emission 520 nm) was measured using a ﬂuorescence microscope
(TE 2000S, Nikon, Melville, NY). Fluorescence images were cap-
tured using a CCD camera (CoolSNAP-ES, Roper Scientiﬁc Photo-
metrics, Tucson, AZ) controlled by a computer with image acquisi-
tion software (NIS Elements, Nikon).
Statistics
All comparisons were performed using Prism 5.0b (GraphPad
Software, La Jolla, CA). We used 1-way ANOVA and Bonferroni’s
test for multiple comparisons. All other comparisons were ana-
lyzed by t-test. Data are presented as mean7SE. Statistical
signiﬁcance was accepted when Po0.05.Results
Neutral sphingomyelinase activity in skeletal muscle
Equal amounts of protein from skeletal muscle, C2C12 myo-
tube, or mouse brain homogenates were assessed for nSMase
activity. nSMase activity was similar in all muscles evaluated
(Fig. 1A). In comparison, the muscle activity is 70% that of
mouse brain (Fig. 1A). This is consistent with brain having
abundant levels of nSMase2 [25]. In myotube extracts, activity at
pH 7.5 exhibited characteristic Mg2þ-dependence, with increasing
activity between 6 and 12 mM MgCl2 (Fig. 1B). Neutral activity at
10 mM MgCl2 was depressed by Triton X-100 (0.1%) and abolished
by 10 mM GW4869, a non-competitive nSMase inhibitor (Fig. 1B).
Neutral sphingomyelinase mRNA in skeletal muscle
In an effort to deﬁne the source(s) of nSMase activity in muscle,
relative expression of nSMase mRNAs were compared. Quantita-
tive real-time PCR analyses detected mRNA for all known nSMases
(nSMase1, Smpd2 gene; nSMase2, Smpd3 gene; nSMase3, Smpd4gene; MA-nSMase, Smpd5 gene); in human and mouse diaphragm
(Fig. 2A). Primer efﬁciencies were similar (91–99% efﬁciency, data
not shown) for each mRNA. In both human and mouse diaphragm,
nSMase3 mRNA was most abundant, being present at levels 5–20
times greater than mRNA of other nSMases. nSMase3 mRNA was
present at similar levels among mouse limb muscles, respiratory
muscle, and myotubes (Fig. 2B). mRNA levels do not always mirror
protein activity; however, these results suggest nSMase3 is an
important source of nSMase activity in muscle.
nSMase3 protein and splice variant expression in skeletal muscle
nSMase3 protein was detected using custom polyclonal anti-
bodies. In SDS-PAGE, nSMase3 antibody detected proteins of 88
and 85 kD (Fig. 3A). The most abundant protein appeared smaller
than expected according to the predicted molecular weight of full-
length mouse nSMase3 (93 kD). Membrane proteins commonly
migrate faster than expected. Their inherent hydrophobicity lends
to high SDS binding and a more compact structure that migrates
faster than size predicts [50]. To conﬁrm antibody speciﬁcity,
myotube lysates were run on non-denaturing PAGE. Under these
conditions a single band of 290 kD was seen by western blot,
indicating possible oligomerization (Fig. 3B). Excision of this band
from the gel followed by activity assay [18] conﬁrmed that the gel
slice contains nSMase activity (Fig. 3C). In addition, myotubes were
transfected with an nSMase3-speciﬁc siRNA (targeting exon 18 of
the Smpd4 gene). Both 88 and 85 kD proteins were depleted by
siRNA (Fig. 3D). Quantiﬁcation shows knockdown of nSMase3
protein was 50% effective (Fig. 3D). These results identify multiple
isoforms and support a role for nSMase3 in skeletal muscle
sphingolipid homeostasis.
The nSMase3 precursor mRNA structure and it is homology
between human and mouse is shown in Fig. 4A. It has a unique
protein:protein interaction domain and a C-terminal transmem-
brane domain that is juxtaposed to the putative active site. In
addition, nSMase3 has a potential N-linked glycosylation site in
exon 17 of the c-terminus (not shown). We tested whether the 88
and 85 kD isoforms are the result of glycosylation. However,
treatment with N-glycosidase F did not alter migration (data not
shown).
Next we tested whether the protein isoforms were derived
from alternative splicing. nSMase3 appears to undergoes complex
RNA processing. NCBI Gene (http://www.ncbi.nlm.nih.gov/gene)
and Aceview list multiple (4 and 17, respectively) coding nSMase3
mRNA sequences (https://www.ncbi.nlm.nih.gov/IEB/Research/
Acembly/). Conventional PCR, cDNA cloning and sequencing, and
real-time PCR demonstrated that mouse skeletal muscle expresses
at least two splice variants (mouse NM_029945.3, NM_001164610.
1; human NM_017951.4, NM_017751.4). Fig. 4B depicts an agarose
gel containing conventional PCR products from ampliﬁcation of
select nSMase3 exons. The labels above each lane indicate the
exons that were ampliﬁed. Multiple bands indicate potential splice
variants. A potential 100 bp deletion is shown between exons 7–12
and 10–13 in human diaphragm and between exons 9 and 13 in
mouse myotubes. These results suggest a conserved splice variant
is expressed in mouse and human skeletal muscle. Ampliﬁcation
and cloning of nSMase3 full-length cDNA resulted in recovery of
two unique cDNA clones fused with an N-terminal GFP (Fig. 4C).
Consistent with the conventional PCR results, DNA sequencing
revealed that the larger clone contains all 20 exons of the nSMase3
coding region (mouse NM_029945.3) while the smaller clone lacks
the 100 bp exon 11 (mouse NM_001164610.1). We have designated
these splice variants nSMase3a and nSMase3b, respectively. Pri-
mers were designed to speciﬁcally detect nSMase3a and b mRNA,
i.e., with or without exon 11. Using these, we conﬁrmed that both
nSMase3a and nSMase3b mRNAs are constitutively expressed in
Fig 1. nSMase activity in skeletal muscle and myotubes. (A) nSMase activity in equal protein from tissues and myotubes assessed via choline release from sphingomyelin
(n¼3). Data are derived using a standard curve generated from serial dilutions of phosphocholine. Po0.02 by ANOVA, n different from human diaphragm and mouse soleus
by Bonferroni’s multiple comparison. (B) Magnesium dependence of myotube nSMase activity (n¼7) and sensitivity to Triton X-100 (0.1%, n¼3) or GW4869 (10 mM, n¼3)
expressed as % control (MgCl2 10 mM). Po0.001 by ANOVA, n different from 0 mM MgCl2, # different from control, by Bonferroni’s multiple comparison.
Fig. 2. nSMase mRNA in skeletal muscle. (A) Real-time PCR of known nSMases in human and mouse diaphragm. (B) Real-time PCR of nSMase3 mRNA in different mouse
skeletal muscles and myotubes (AU¼arbitrary units, n¼13 for human tissues, n¼4 for mouse, n¼3 for myotubes). Abundances are normalized to rpl13A. n Po0.0001 by
ANOVA.
Fig. 3. nSMase3 protein expression. (A) Western blot showing detection of a doublet using custom polyclonal nSMase3 antibodies. (B) Western blot under non-denaturing
PAGE conditions shows migration of native nSMase3. (C) nSMase activity in non-denaturing gel slices of anti-nSMase3 reactive band compared to activity of non-speciﬁc gel
slice (choline release, n¼6), n Po0.02. (D) siRNA speciﬁc for nSMase3 depletes the anti-nSMase3 reactive doublet. Sample volumes for western blot were adjusted for equal
total protein, total protein was assessed by SDS-PAGE and simply blue staining (n¼6, n Po0.001).
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Fig. 4. nSMase3 splice variant expression. (A) Structure of precursor mRNA for human and mouse nSMase3. Unﬁlled boxes represent untranslated regions (UTR); ﬁlled boxes
are exons; lines are introns (scaled to 1/4 size relative to exons). Inverted blue carets indicate alternatively spliced exons. Below the maps are exon numbers. (B) Agarose gel
shows human and myotube cDNA subjected to conventional PCR with primers that amplify select nSMase3 splice junctions (see Table 1). Numbers above the gels indicate
the exon location for forward and reverse primers. Multiple bands indicate alternative splicing. (C) Western blot with anti-GFP shows expression of nSMase3 splice variant
GFP-fusion clones. (D) Real-time PCR of nSMase3 splice variants. A forward primer in exon 11 and a reverse primer in exon 12 detects nSMase3a; a forward primer that spans
the exon 10–exon 12 splice junction and a reverse primer in exon 12 detects nSMase3b (see Table 1; n¼6 for human tissues, n¼4 for mouse, n¼3 for myoblasts or
myotubes), n Po0.05 vs. nSMase3a. (E) Western blot and total protein of extracts from siRNA treated myotubes, siRNAs (20 nM) targeted nSMase3a and b (exon 18) or
nSMase3a (exon 11). siRNA primer sequences are listed in Table 1. (F) Quantiﬁcation of E (n¼9 control siRNA, n¼6 exon 18 siRNA, n¼3 exon 11 siRNA), n Po0.05 vs. control.
J.S. Moylan et al. / Redox Biology 2 (2014) 910–920 915muscle. The data are shown in Fig. 4D. Human muscle, mouse
muscle, and myotubes express more nSMase3a than b whereas
myoblasts express the variants at equal levels.
The predicted molecular weights of nSMase3a and b corre-
spond to the 88 and 85 kD isoforms recognized by the nSMase3
antibody (Fig. 3). To conﬁrm the identity of these proteins,
myotubes were transfected with siRNA targeting nSMase3a and
b (exon 18) or nSMase3a only (exon 11). Western blot of extracts
from transfected myotubes showed that exon 18 siRNA depleted
both isoforms, while exon 11 siRNA depleted only the 88 kD
protein (Fig. 4E and F). These results indicate the 88 kD protein
is nSMase3a and the 85 kD protein is nSMase3b. In agreement
with the mRNA data, nSMase3a is more abundant than nSMase3b.
nSMase3 distribution
Fig. 5A demonstrates that nSMase3a and b distribute differently
between cellular fractions. The cytosolic fraction contained the
majority of total myotube protein (8470.7% SEM) and cytosolic
p38 MAPK but no detectable levels of nSMase3. A portion of
nSMase2 was found in the cytosol. The detergent-soluble fraction
contained 9% (70.1 SEM) of total protein and membrane proteins
commonly associated with sarcolemma (TNF receptor 1, TNFR1),
mitochondria (voltage dependent anion channel, VDAC), endo-
plasmic reticulum (ER retention amino acid sequence, KDEL), orcaveolae (caveolin). Approximately 12% of total nSMase3 protein
composed of equal amounts of nSMase3a and b were found in the
soluble fraction. The detergent-resistant fraction, which contained
6% (70.1 SEM) of total protein, is reported to have proteins
concentrated in caveolin-, cholesterol-, and sphingolipid-rich
membranes [46–48]. These membrane regions are considered
hot spots for receptor-mediated signaling [35]. Correspondingly,
we ﬁnd a small proportion of TNFRI in the detergent resistant
fraction and a majority of caveolin. It is also enriched with proteins
of the Golgi (giantin) and nucleus (lamin A/C) (Fig. 5A). This
fraction contained the majority (88%) of total nSMase3 and was
composed primarily of nSMase3a. These data suggest that nSMa-
se3a and b may serve different functions in myotube sphingolipid
metabolism.
The distribution of nSMase activity per fraction is consistent
with nSMase3 protein localization. The majority of activity is in
the detergent-resistant fraction (8271.8%, Po0.0001). A minor
portion (18%) is cytosolic and may be attributed to cytosolic
nSMase2. Detergent-soluble activity was undetectable, likely due
to Triton in the sample.
Immunoﬂuorescence staining also demonstrated discrete cel-
lular localization. nSMase3 antibody stained mouse diaphragm in
a punctate pattern within and on the periphery of the myoﬁber
(Fig. 4D). Interior nSMase3 staining did not co-localize with inner
mitochondrial membrane structures as revealed by co-staining
Fig 5. Distribution of nSMase3 in cellular fractions. (A) Western blot of myotube fractions. Antibodies to proteins that reside in discreet compartments show the composition
of fractions. (B) Quantiﬁcation of nSMase3 protein detected in A (n¼6, n Po0.0001 vs. detergent-soluble fraction and nSMase3b). (C) nSMase activity per fraction (choline
release, n¼3, n Po0.0001 vs. cytosol). (D) Upper panel: immunoﬂuorescent staining of mouse diaphragm sections with anti-nSMase3 (green) and anti-ATP synthase-α (red).
Nuclei are stained with DAPI (blue). Inset 1 shows location relative to inner mitochondrial membrane. Lower panel: co-staining with nSMase3 (green) and annexin 2 (red)
antibodies. Inset 2 shows nSMase3 staining near the plasma membrane, inset 3 shows perinuclear staining. Upper right panel, secondary antibodies only. Scale bar¼10 mm.
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staining near the plasma membrane overlapped with staining for
annexin 2, a cytoskeletal protein that localizes to the inner and
outer plasma membrane (Fig. 4D, lower panel and inset 2).
nSMase3 staining also surrounded some nuclei (Fig. 4D, lower
panel and inset 3, blue DAPI stain). These data support prior
reports that nSMase3 does not localize to the mitochondria but
rather to mitochondrial-associated ER membranes [8,11,31] and
also suggest some sarcolemmal and perinuclear localization.
nSMase3 activity
GFPnSMase3 variants expressed in myotubes localized in
punctate clusters (Fig. 6A) similar to staining patterns of the
endogenous protein in mouse diaphragm (Fig. 5D). Western blot
using the nSMase3 antibody conﬁrms GFPnSMase3 proteins are
overexpressed relative to endogenous nSMase3 (Fig. 6B).
GFPnSMase3a is functionally active. This is shown in Fig. 6D where
overexpression of nSMase3a led to elevated nSMase activity.Overexpression of nSMase3b tended to increase activity but this
increase was not statistically signiﬁcant. Quantiﬁcation of
GFPnSMase3 overexpression (Fig. 6C) showed that overexpression
of GFPnSMase3b was greater than GFPnSMase3a (18076%,
Po0.001), but activity was slightly lower (Fig. 6C). Thus there
may be differences in enzymatic properties of the variants.
nSMase3 and receptor-mediated signaling
TNF stimulates cytosolic oxidant activity in skeletal muscle, a
response that is detectable within minutes and is mediated via
TNF receptor subtype 1 [23,34]. Similarly, Ferreira et al. have
shown that direct exposure to bacterial SMase or exogenous
ceramide also increases oxidant activity [17]. These reports im-
plicate signaling lipids as receptor-activated regulators of skeletal
muscle oxidant production. Our current data suggests this process
is regulated by nSMase3. Data in Figs. 7–9 support this idea. Fig. 7
describes TNF-stimulated nSMase activity (Fig. 7A) and conﬁrms
that TNF or C2-ceramide increase oxidant activity (Fig. 7B).
Fig. 6. nSMase3 splice variant activity. (A) Fluorescence images of GFPnSMase3a and GFPnSMase3b in myotubes (scale bar¼100 mm). (B) Western blot of lysates transfected
with GFPnSMase3a or b using anti-nSMase3. (C) Quantiﬁcation of B (n¼3), Po0.001 vs. GFPnSMase3a. (D) nSMase activity in lysates from myotubes transfected with
GFPnSMase3a or GFPnSMase3b (choline release, n¼6), n Po0.05 vs. GFP control.
Fig. 7. TNF, sphingomyelin, and oxidant signaling. (A) TNF-induced nSMase activity in myotubes, 5 min pretreatment of TNF (6 ng/ml, choline release, n¼9), nPo0.05.
(B) Increased oxidant activity in C2C12 myotubes pretreated for 20 min with TNF (6 ng/ml) or C2-ceramide (10 mM). Measured by DCF ﬂuorescence assay, each treatment was
applied to 12-wells of cultured myotubes, the 5 brightest myotubes per well were analyzed, each data point is an average of these 5 myotubes (RFU¼relative ﬂuorescence
units), nPo0.02 vs. untreated, paired comparison.
Fig. 8. TNF, nSMase3, and oxidant signaling. (A) nSMase activity in myotubes transfected with vehicle (Endo-Porter) or nSMase3 morpholino (10 mM)7TNF (6 ng/ml, 15 min,
n¼6, choline release assay, Po0.0001 by ANOVA, n different from control, # different from TNF-treated vehicle, by Bonferroni’s multiple comparison). (B) Quantiﬁcation
oxidant activity from myotubes transfected with vehicle (Endo-Porter) or nSMase3 morpholino (10 mM)7TNF (6 ng/ml, 20 min). (C) Representative images of myotubes
transfected with vehicle (Endo-Porter), nSMase2, or nSMase3 morpholino7TNF. (D) Quantiﬁcation of oxidant activity from myotubes transfected with vehicle (Endo-Porter)
or nSMase2 morpholino (10 mM)7TNF. Oxidant activity analysis was performed as in Fig. 7B.
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nSMase activity (Fig. 8A) and oxidant production (Fig. 8D). Fig. 8C
shows representative ﬂuorescence images of control and TNF-
treated myotubes transfected with vehicle (Endo-Porter), nSMase2
morpholino, or nSMase3 morpholino. Vehicle or nSMase2 mor-
pholino controls demonstrate that depression of oxidant activity is
speciﬁc for the nSMase3 morpholino (Fig. 8D).
To conﬁrm the morpholino results, myotubes were transfected
with nSMase3a siRNA (exon 11). TNF stimulated both nSMaseactivity (Fig. 9A) and oxidant production (Fig. 9B) in control
myotubes but failed to do so in myotubes transfected with
nSMase3a siRNA. We were unable to determine if nSMase3b
contributes to oxidant signaling because an siRNA designed to
target design an nSMase3b speciﬁc siRNA. However, siRNA knock-
ing down both nSMase3a and 3b (exon 18) reduced oxidant
production to the same degree as nSMase3a siRNA alone (data
not shown), suggesting nSMase3a is sufﬁcient to mediate TNF-
stimulated oxidant production.
Fig. 9. nSMase3a and oxidant signaling. (A) nSMase activity in myotubes transfected with control or siRNA to nSMase3a (exon 11, 20 nM)7TNF (6 ng/ml, 5 min, n¼4,
ceramide release assay, Po0.002 by ANOVA, n different from untreated, #different from TNF-treated control siRNA by Bonferroni’s multiple comparison). (B) Oxidant activity
in myotubes transfected with control or siRNA to nSMase3a (as in A)7TNF (6 ng/ml, 20 min, n¼9 per group, n Po0.001, paired comparisons). Oxidant activity analysis was
performed as in Fig. 7B.
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Muscle nSMase activity has been detected in rabbit hind limb
muscles [18], rat soleus and gastrocnemius [15], and human vastus
lateralis [24]. In this report, we compared nSMase activity in
mouse brain, diaphragm, extensor digitorum longus (EDL), soleus,
and human diaphragm. We found that mouse muscle exhibits
signiﬁcant nSMase activity similar to that of human diaphragm
and 70% that of mouse brain. Muscle SMase activity has character-
istics that are typically observed for a magnesium-dependent
nSMase. The importance of nSMase in regulating cell function,
especially cellular stress responses, has long been known. Recent
research has shown that nSMases are a family of proteins with
similar enzyme activity, but with seemingly distinct function in
sphingolipid homeostasis and signaling. The nSMase3 isoform was
cloned in 2006 [31]; this report suggested that nSMase3 was
preferentially expressed in muscle. Our data indicate that nSMase3
contributes to the overall nSMase activity in muscle. The support-
ing evidence is as follows: (i) comparison of all four nSMase
isoforms in muscle shows that nSMase3 mRNA is abundantly
expressed; (ii) overexpression of nSMase3 in myotubes elevates
overall nSMase activity; (iii) depletion of nSMase3 using siRNA
decreases nSMase activity.
In skeletal muscle, sphingolipids appear to be important
mediators of TNF signaling. For example, the response of murine
muscle to TNF, i.e., increased oxidant production, is mimicked by
direct exposure to either C6-ceramide or bacterial Smase [17,23].
Our current experiments demonstrate that TNF stimulates endo-
genous nSMase activity. We attribute some of this to nSMase3
since nSMase3 silencing prevents the rise in activity. Finally we
show that nSMase3 is essential for the rise in cytosolic oxidant
activity stimulated by TNF. By two independent methods, nSMase3
morpholino or nSMase3 siRNA, we show that depletion of
nSMase3 abolishes the increase in oxidants after TNF exposure.
In aggregate, these ﬁndings provide evidence for a TNF–nSMase3-
oxidant pathway.
Instead of nSMase3, the nSMase2 isoform has been shown to
mediate TNF action in non-muscle cell types [9]. Our data do not
exclude the possibility that nSMase2 mediates other TNF functions
in muscle. The two enzymes vary in their predicted structures and
subcellular localizations, suggesting different roles in signaling and
distinct mechanisms of regulation. In particular, nSMase2 has two
transmembrane domains and N-palmitoylation is required for
membrane attachment [59]. Regulated transport of nSMase2 tothe plasma membrane is required for signaling [10,38]. In contrast,
nSMase3 is a c-tail-anchored membrane protein. Such proteins
localize to target membranes after full emergence and release
from the ribosome into the cytosol [review [6]]. Tail-anchored
proteins localize either unassisted or by chaperone to structures
that include ER, outer mitochondrial, and peroxisomal mem-
branes. From the ER, these proteins can be transported to the
Golgi and plasma membrane.
Our data lend support to previous studies that report multiple
locations for nSMase3. Using cell fractionation and immunoﬂuor-
escence staining of the endogenous protein, we found sites near
the plasma membrane, perinuclear region, and areas surrounding
mitochondria. A peri-mitochondrial relationship was also reported
by Chipuk et al. [8]. They found endogenous nSMase3 in mito-
chondrial-associated ER membranes from mouse liver. Others
have found GFP-tagged nSMase3 in ER and Golgi membranes
[8,11,31]. The variety of reported locations may reﬂect the large
number of potential nSMase3 isoforms predicted by Aceview and
NCBI Gene. Alternatively, the apparent ubiquity in membrane sites
could indicate an important role for nSMase3 in sphingolipid
homeostasis of cellular membranes.
nSMase-generated ceramide species are not thought to travel
from their site of production. Thus the location of nSMase3 could
provide clues as to the source of oxidant production. For example,
ceramide generated at the plasma membrane might alter mem-
brane properties to allow for assembly and clustering of NADPH
oxidase subunits [28] or might allow calcium inﬂux and nNOS
activation [16]. Alternatively, ER-localized nSMase3 might activate
intracellular ER-associated NADPH oxidase [21]. A growing body of
evidence points to mitochondria as a major source of reactive
oxygen species in skeletal muscle [32,39,49]. Thus, nSMase3 found
in mitochondria-associated ER membranes [8] might alter mem-
brane properties to stimulate mitochondrial oxidant production.
Finally, our study conﬁrms the expression of alternative
nSMase3 transcripts. Multiple validated splice variants for
nSMase3 are reported in NCBI Gene. We ﬁnd that at least two of
these, designated nSMase3a and nSMase3b, are constitutively
expressed in skeletal muscle and appear to distribute differently.
nSMase3a fractionates with proteins of cholesterol-rich (caveolin),
and Golgi (giantin) membranes. nSMase3b distributes more
equally and co-fractionates with mitochondrial (VDAC), ER (KDEL),
and plasma membrane (TNFRI) proteins. Different localization
patterns suggest that nSMase3a and nSMase3b may serve separate
functions, respond to different stimuli, or hydrolyze distinct
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tion may depend upon epigenetic mechanisms of regulation that
have not yet been identiﬁed.Conclusions
In summary, our data demonstrate nSMase activity in skeletal
muscles of humans and mice. We show that nSMase3 mRNA is
highly expressed in skeletal muscle. We suggest that sphingolipid
signaling in skeletal muscle is derived in part from nSMase3 and
that nSMase3 regulates skeletal muscle oxidant production. Oxi-
dants are important mediators of TNF effects in skeletal muscle,
modulating force production [23,52] and muscle quality [5]. Prior
to our study, signaling intermediates between TNF-receptor bind-
ing and oxidant production had not been identiﬁed. We identify
nSMase3 as an important mediator of TNF/redox signaling that
may prove critical for redox-sensitive aspects of muscle function.Conﬂict of interest
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